OncoMatch/Clinical Trials/NCT05871021
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Is NCT05871021 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for glioblastoma.
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically. The goal is improved survival without significantly increasing side effects. The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per fraction.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: MGMT unmethylated
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: vegf inhibitor (bevacizumab)
Lab requirements
Blood counts
Neutrophil counts >1500/µl, Platelet counts >100,000/µl, Hemoglobin > 8 g/dl
Kidney function
Serum creatinine <1.5-fold ULN; Serum creatinine ≤ 1.5 x ULN AND patients with urine dipstick for proteinuria < 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should show urine protein to creatinine ratio ≤ 1
Liver function
Bilirubin, AST or ALT <2.5-fold ULN unless attributed to anticonvulsants; Alkaline phosphatase <2.5-fold ULN
Neutrophil counts >1500/µl, Platelet counts >100.000/µl, Hemoglobin > 8 g/dl, Serum creatinine <1.5-fold upper limit of normal (ULN), Bilirubin, AST or ALT <2.5-fold ULN unless attributed to anticonvulsants, Alkaline phosphatase <2.5-fold ULN; Serum creatinine ≤ 1.5 x ULN AND patients with urine dipstick for proteinuria < 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should show urine protein to creatinine ratio ≤ 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify